The nature of the clinical research process means that the Principal Investigator holds the primary responsibility for the accurate determination of the proper allocation of the direct costs of clinical trials and clinical research studies. In his or her dual role as physician and investigator, the Principal Investigator is responsible for making a timely and accurate determination of the appropriate portion of patient, professional, and technical fees, and other clinical costs that are directly and solely attributable to the study. As long as the costs are allowable under the terms of the agreement between the sponsor and MUSC, all incremental or additional clinical expenditures arising from a patient being included in a study must be charged directly to the Sponsored Project UDAK and not to the patient, Medicare/Medicaid, and other third party payors.
Examples of incremental charges that must be charged to the Sponsored Project include:
a. Fees relating to additional hospital services directly associated with the patient being included in the clinical trial that otherwise would not have been necessary for the patient?s care (e.g., additional room and board);
b. Fees relating to the particular item or service being investigated (e.g., cost of the drug or treatment under the study); and,
c. Fees relating to items and services provided solely to satisfy data collection needs not otherwise necessary for the patient?s care (e.g., additional laboratory and diagnostic testing required by the study's protocol but not necessary for conventional patient care).
Questions regarding allocation of clinical costs should be addressed to the appropriate Grants and Contracts Accounting Accountant based on departmental assignment. (see Distribution of Grants by Administrator) or at 792-2850.